A phase II/III study of SHP-616 (CINRYZE) for Acute Neuromyelitis Optica

Trial Profile

A phase II/III study of SHP-616 (CINRYZE) for Acute Neuromyelitis Optica

Planning
Phase of Trial: Phase II/III

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs Complement C1 inhibitor protein (Primary)
  • Indications Neuromyelitis optica
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2015 New trial record
    • 15 Dec 2015 According to a Shire media release, Shire plans to initiate this study in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top